Airborne Preventive Measures to Reduce New TB Infections in Household Contacts

NCT ID: NCT04938596

Last Updated: 2024-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

432 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-04

Study Completion Date

2024-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case, can reduce new TB infections in close contacts. For this purpose, a pilot, controlled, pre-post study will be set up, to evaluate the feasibility of implementing a bundle of respiratory precautions to all household contacts of new pulmonary TB cases, compared to standard of care, in primary health care in a high TB incidence area in Santiago, Chile.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). In 2018, an estimated 10 million people fell ill with TB worldwide, and more than 1.4 million people died from it, making eradication of this disease in the next decades highly unlikely unless new interventions are discovered. Mycobacterium tuberculosis (Mtb) transmission mainly occurs when patients affected by laryngeal or pulmonary TB cough upon others and the mycobacteria are spread in airborne droplets nuclei smaller than 5 μm that are subsequently inhaled by close contacts. Although chemoprophylaxis once a new TB infection is detected is an effective strategy to reduce the risk of contacts developing active TB, it does not prevent Mtb acquisition; it only reduces the risk of developing active TB once infected. Currently, the large majority of international guidelines recommend strict measures to reduce airborne transmission in hospitalized patients with pulmonary TB, with a minimum of 2 weeks of effective TB therapy to consider a patient no longer infectious and discontinue respiratory isolation in healthcare settings. On the contrary, in the community, no special recommendations regarding protection of household contacts are specified, assuming that most of them are already infected and that the TB index case will stop infecting very quickly under antimicrobial treatment. However, several studies show that median time to sputum Mtb culture conversion under effective treatment takes 5-7 weeks, raising the potential for continued transmission even despite effective treatment. Furthermore, a previous study has shown that in Santiago, Chile, 55% of household contacts of TB cases have no evidence of TB infection at the time of diagnosis of the index case - as categorized by negative latent TB testing - yet under close follow-up, up to 21% of these show new evidence of having acquired the infection based on latent TB test conversion after 12 weeks of follow-up. The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case, can reduce new TB infections in close contacts. For this purpose, a pilot, controlled, pre-post study will be done to evaluate the feasibility of implementing a bundle of respiratory precautions to all household contacts of new pulmonary TB cases, compared to standard of care, in primary care in a high TB incidence area in Santiago. The respiratory bundle in the intervention arm will be implemented as soon as a new pulmonary TB case is diagnosed, will last 2 weeks and, will include: (a) provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, (b) recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others, (c) promotion of strategies to improve house ventilation; and (d) education about TB transmission. The investigators expect to show that this trial is feasible to proceed with a larger, definitive cluster randomized controlled trial that will evaluate the intervention effectiveness in reducing the incidence of new TB infections in household contacts. The results of this study will help to answer a critical research gap in TB infection control and prevention and, it will provide a key contribution to future policies regarding TB control and elimination worldwide. Furthermore, in the new global context of rising infectious agents of pandemic risk, this work may have an additional potential relevance with respect to the use, acceptability and transmission prevention potential of a respiratory bundle in the household setting regarding other respiratory pathogens such as SARS-Cov-2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis, Pulmonary Household Contacts Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, semi-experimental, controlled trial.

Two different health care areas of Santiago (and their corresponding TB clinics) will be allocated to control or intervention arm; after a baseline pre-intervention period.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Respiratory Bundle Group

The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.

Group Type EXPERIMENTAL

Respiratory bundle

Intervention Type COMBINATION_PRODUCT

* Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks
* Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks
* Promotion of strategies to improve house ventilation during 2 weeks
* Provision of a TB leaflet and nurse education about TB transmission.

Standard of care

Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Respiratory bundle

* Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks
* Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks
* Promotion of strategies to improve house ventilation during 2 weeks
* Provision of a TB leaflet and nurse education about TB transmission.

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all household contacts of a new case of pulmonary TB (smear, culture or PCR positive) newly diagnosed at each clinic.

Exclusion Criteria

* household contacts found to have co-prevalent active TB at enrolment
* household contacts planning to leave the house at the time of enrolment
* household contacts of index cases having already initiated TB treatment for \> 48h
* household contacts of index cases that are currently hospitalized
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

OTHER_GOV

Sponsor Role collaborator

Agencia Nacional de Investigación y Desarrollo

OTHER

Sponsor Role collaborator

Pontificia Universidad Catolica de Chile

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

María Elvira Balcells, MD; MSc

Role: PRINCIPAL_INVESTIGATOR

School of Medicine. Pontificia Universidad Católica de Chile.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pontificia Universidad Católica de Chile

Santiago, , Chile

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Chile

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1211225

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.